ClinicalTrials.gg
Active, not recruitingNCT07119372Updated Sep 1, 2026

Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

A Phase 3 interventional study of BCD-131 (pegdarbepoetin beta) and Mircera (methoxypolyethylene glycol-epoetin beta) in Anemia, Chronic Kidney Disease and Chronic Kidney Disease Patients on Hemodialysis, sponsored by Biocad. Active, not recruiting at 14 sites in Russia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2025, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.

Read the detailed description

This study is designed to test the hypothesis that BCD-131 is non-inferior to Mircera for the treatment of anemia in patients with end-stage renal disease on dialysis, with the primary assessment occurring at Weeks 28-32 of treatment. Eligible subjects will have Stage 5 Chronic Kidney Disease (CKD) and will have been receiving dialysis (a minimum frequency of 3 sessions per week and at least 12 hours per week of standard hemodialysis, with a stable dialysis prescription) for at least 90 days prior to informed consent form (ICF) signature. Subjects must have anemia of renal origin with no other identifiable causes of anemia (including anemia of chronic disease, vitamin B12 deficiency, folic acid deficiency, or iron deficiency, etc.).

This study evaluates the efficacy of BCD-131 as maintenance therapy. Eligible patients must have received stable doses of erythropoiesis-stimulating agents (erythropoietin alfa, erythropoietin beta, or darbepoetin alfa) for at least 3 months prior to ICF signature and throughout the screening period, with target hemoglobin levels (100-120 g/L) maintained for at least 2 weeks prior to and at the time of screening.

The study comprises the following periods:

  • Screening period (up to 28 days).
  • Main treatment period (Weeks 0-32).
  • Extension period (Weeks 33-84) for long-term safety and efficacy assessment. • Follow-up period (28 days after last investigational product dose at Week 84).
02

Conditions studied

  • Anemia
  • Chronic Kidney Disease
  • Chronic Kidney Disease Patients on Hemodialysis
  • Chronic Kidney Disease 5D

Keywords

  • Chronic Kidney Disease
  • CKD
  • Anemia
  • Erythropoietin
  • Darbepoetin
  • Erythropoiesis-stimulating agent
  • Dialysis
  • Hemodialysis
  • Renal anemia
03

In context

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

This study's planned enrollment of 228 is above the median of 117 across 1,336 interventional studies indexed under Anemia.

Browse Anemia studies →

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient signed a written ICF for participation in the study.
  • Men and women aged 18 to 75 years inclusive at the time of signing the ICF.
  • End stage kidney disease (documented).
  • The need for dialysis sessions within at least the last 90 days prior to signing the ICF.
  • For patients on hemodialysis - hemodialysis procedures should be at least 3 times a week, for a total duration of at least 12 hours a week.
  • Documented use of recombinant erythropoietin (epoetin alfa, epoetin beta or darbepoetin alfa) for at least 90 days prior to signing the ICF.
  • The dose of recombinant erythropoietins (epoetin alfa or epoetin beta received 1, 2 or 3 times a week, or darbepoetin alfa received once a week/once every 2 weeks) should be stable for at least 90 days prior to signing the ICF and the entire screening period (documented).
  • Target level (100-120 g/L inclusive) based on the results of screening examination (two measurements).
  • The efficacy of dialysis established at screening or not more than 14 days before signing the ICF (dialysis dose index (Kt/v) ≥1.2 in patients on long-term hemodialysis, and weekly Kt/v ≥1.7 for patients on peritoneal dialysis).
  • Transferrin saturation ≥20%, ferritin level >100 ng/mL at screening.
  • Cyancobalamine (vitamin B12) and folic acid levels within the laboratory reference values at screening.
  • Willingness of patients of both sexes and their sexual partners of to use methods of in accordance with the protocol, starting from signing the form, throughout the study and for up to 90 days after receiving the last dose of the drug in the clinical study, as well as to refrain from donation of eggs for female subjects or sperm for male subjects during this period.
  • The ability of the patient to comply with the Protocol requirements, in the Investigator's opinion.

Exclusion criteria

Exclusion Criteria:

  • Any other diagnosed forms of anemia, except for anemia of renal disease, including anemia in chronic diseases (C-reactive protein level >20 mg/L at screening).
  • Diagnosed lupus nephritis or chronic kidney disease due to systemic vasculitis.
  • count \<100×10\^9/L based on the results of screening examination.
  • A high probability of early withdrawal from the study, in particular a planned (i.e., available information about a planned date and/or a suitable donor) kidney transplant surgery during the estimated period of participation in the study.
  • A history of severe allergic reactions (anaphylactic shock or multiple drug allergy) according to the patient, and to recombinant erythropoietins, polyethylene glycol or any components of the study drugs, or to iron (III) hydroxide sucrose complex.
  • Vaccination less than 8 weeks before signing the ICF (according to the patient).
  • Diagnosed liver cirrhosis.
  • infection.
  • , AST >3х at screening.
  • Decompensated heart disease ( Class IV CHF).
  • Resistant hypertension.
  • Unstable angina.
  • History of acute hemolysis episodes.
  • Documented hemoglobinopathy, myelodysplastic syndrome, hematological , pure red cell aplasia.
  • Severe secondary hyperparathyroidism (intact PTH>1000 pg/mL at screening) or -confirmed bone marrow fibrosis (myelofibrosis).
  • Documented episodes of gastrointestinal or other bleeding within less than 90 days prior to signing the ICF.
  • Documented history of episodes of thrombosis (acute myocardial infarction, stroke, , deep vein thrombosis, pulmonary thromboembolism within less than 6 months before the signing of the ICF, as well as long-term vascular access thrombosis within 30 days before the signing of the ICF.
  • Seizure syndrome, including a history of or epilepsy during the screening period.
  • Documented major surgery less than 30 days before signing the ICF.
  • Documented blood transfusion within less than 90 days prior to signing the ICF.
  • Any acute or chronic infections in the stage of exacerbation, as well as other chronic diseases that at the time of signing the , may adversely affect the patient's safety while using the study therapy in the opinion of the investigator.
  • A history of severe depression, suicidal ideation, or attempted suicide.
  • Documented malignancies other than cured basal-cell carcinoma and/or cervical carcinoma in situ with a remission duration of more than 5 years at the time of signing the ICF.
  • Known alcohol or drug addiction, or current signs of alcohol/drug addiction, which, according to the investigator, is for the treatment with the test drug/reference drug or limits the treatment adherence.
  • Participation in other clinical studies of medicinal products within less than 90 calendar days prior to signing the informed consent form for participation in this study.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (estimated)

Study arms

  • Experimental
    BCD-131

    BCD-131 (pegdarbepoetin beta)

    Biological: BCD-131 (pegdarbepoetin beta)

  • Active comparator
    Mircera

    Mircera (methoxypolyethylene glycol-epoetin beta)

    Biological: Mircera (methoxypolyethylene glycol-epoetin beta)

Interventions

  • BiologicalBCD-131 (pegdarbepoetin beta)

    BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 84 weeks

  • Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks up to Week 48 inclusive; starting from Week 52, all subjects will be switched to BCD-131 treatment up to Week 84 inclusive.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)

    Time frame: During the assessment period at Weeks 28-32

Secondary outcomes

  1. Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)

    Time frame: Weeks 48-52

  2. Proportion of subjects (%) with a mean hemoglobin level at the time of assessment within the range of ±10 g/L from baseline

    Time frame: Weeks 28-32

  3. Proportion of subjects (%) who required dose adjustment of the test drug/reference drug during the maintenance therapy stage of the main study period

    In the main study period, a dose adjustment is expected during the first 12 weeks of therapy (titration phase), and a maintenance therapy stage is expected during the subsequent weeks of the main study period.

    Time frame: Weeks 12-32

  4. Proportion of subjects (%) who required dose adjustment of the test drug/reference drug during the extension study period

    Time frame: Weeks 33-52

  5. Proportion of subjects (%) who required blood transfusion during the main study period

    Time frame: Weeks 0-32

  6. Proportion of subjects (%) who required blood transfusion during the entire study

    Time frame: Weeks 0-52

  7. The mean hemoglobin level during the main study period

    Time frame: Weeks 0-32

  8. The mean hemoglobin level during the entire study

    Time frame: Weeks 0-52

  9. Proportion of subjects (%) with hemoglobin values greater than 130 g/L and with values greater than 140 g/L during the main study period

    Time frame: Weeks 0-32

  10. Proportion of subjects (%) with hemoglobin values greater than 130 g/L and with values greater than 140 g/L during the entire study

    Time frame: Weeks 0-52

  11. Proportion of subjects with reported AEs/SAEs, which, according to the investigator, are related to the study drugs

    Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88

  12. Proportion of subjects in each group who developed CTCAE v. 5.0 grade 3-4 AEs, which, in the investigator's opinion, are related to the use of the study drugs

    Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88

  13. Proportion of subjects in each group who prematurely withdrew due to AEs/SAEs

    Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88

  14. Frequency of arterial and venous thrombotic complications (cerebrovascular accident, vascular access thrombosis, etc.)

    Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88

  15. Frequency of non-fatal myocardial infarction, death from cardiovascular diseases, death from any cause

    Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88

  16. The Proportion of BAb- and NAb-positive Patients

    Blood sampling for immunogenicity assessment (binding antibodies \[BAbs\] or neutralizing antibodies \[NAbs\]) will be performed before the first injection (Week 0) and then at Weeks 12, 24, 36, and 52

    Time frame: Weeks 0, 12, 24, 36, 52, 64, 76

  17. Proportion of subjects (%) with a mean hemoglobin level at the time of assessment within the range of ±10 g/L from baseline

    Time frame: Weeks 48-52

Other outcomes

  1. Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)

    Time frame: Weeks 80-84

  2. Proportion of subjects (%) who required dose adjustment of the investigational product after switching from Mircera to BCD-131

    The switch from Mircera to BCD-131 occurs at Week 52, followed by a 12-week titration period during which dose adjustments are expected. This titration period is excluded from the assessment of this outcome measure.

    Time frame: Weeks 64-84

  3. Proportion of subjects (%) who required blood transfusion after switching from Mircera to BCD-131

    Time frame: Weeks 52-84

  4. Mean hemoglobin level

    Time frame: Weeks 52-84, Weeks 0-84

  5. Proportion of subjects (%) with hemoglobin levels of >130 g/L and >140 g/L

    Time frame: Weeks 52-84, Weeks 0-84

07

Study locations

14 sites
  • Limited Liability Company "Medical Center "NEFROS"
    Krasnodar, Russia
  • Limited Liability Company Medical Center "NEPHROS"
    Krasnodar, Russia
  • Limited Liability Company "Nephroline-Sibir"
    Novosibirsk, Russia
  • State Autonomous Healthcare Institution Orenburg Regional Clinical Center of Surgery and Traumatology
    Orenburg, Russia
  • "All-Russian Center for Emergency and Radiation Medicine named after A.M. Nikiforov" of the Ministry of Emergency Situations of the Russian Federation
    Saint Petersburg, Russia
  • Limited Liability Company "Kupchinsky Outpatient Dialysis Center"
    Saint Petersburg, Russia
  • Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin
    Saint Petersburg, Russia
  • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"
    Saint Petersburg, Russia
  • Saint Petersburg State Budgetary Healthcare Institution "S.P. Botkin Clinical Infectious Diseases Hospital"
    Saint Petersburg, Russia
  • St. Petersburg City Hospital No. 26
    Saint Petersburg, Russia
  • State Budgetary Healthcare Institution "Volgograd Regional Uronephrological Center"
    Volgograd, Russia
  • Limited Liability Company "Medical Diagnostic Center"
    Yaroslavl, Russia
  • Limited Liability Company "FAMILY CLINIC"
    Yekaterinburg, Russia
  • Sverdlovsk Regional Clinical Hospital No. 1
    Yekaterinburg, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2026, 14 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 14 months is below that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 13, 2025
StartActual
Mar 1, 2025
Primary completionActual
May 12, 2026
CompletionEst.
Oct 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07119372
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Mar 1, 2025
Primary completion
May 12, 2026
Completion
Oct 2027 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion